Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filedfiledCritical
Priority to ECSP003616priorityCriticalpatent/ECSP003616A/en
Publication of ECSP003616ApublicationCriticalpatent/ECSP003616A/en
Pharmaceuticals Containing Other Organic And Inorganic Compounds
(AREA)
Abstract
El empleo de una cantidad terapéuticamente efectiva de IFN-alfa o PEG-IFN -alfa en asociación con una cantidad terapéuticamente efectiva de una sal farmacéuticamente aceptable o profármaco de ácido micofenólico para la preparación de medicamentos para tratar pacientes con enfermedades hepáticas. Loas componentes que administran durante un periodo de tiempo por lo menos suficiente para reducir la cantidad de HCV-RNA presente en la sangre periférica de dicho paciente a menos de 100 copias/ml a 24 semanas después de terminar el tratamiento.The use of a therapeutically effective amount of IFN-alpha or PEG-IFN-alpha in association with a therapeutically effective amount of a pharmaceutically acceptable salt or prodrug of mycophenolic acid for the preparation of medicaments for treating patients with liver diseases. The components administered for a period of time at least sufficient to reduce the amount of HCV-RNA present in the peripheral blood of said patient to less than 100 copies / ml at 24 weeks after the end of treatment.
ECSP0036162000-08-112000-08-11
MOFETIL MYCOPHENOLATE IN ASSOCIATION WITH PEG-IFN-ALFA
ECSP003616A
(en)
Pharmaceutical composition process for providing an antihistamine treatment which does not induce any significant cardiac arrhythmia in a human patient and use of a composition for the manufacture of a medicine for use in an antihistamine treatment
Method of reducing blood cholesterol and / or other blood glycerides in a mammal individual, preparation in the form of a dosage unit, and, set to orally administer the same